Qiagen Launches Colorectal Cancer Companion Diagnostic With PMA Approval
This article was originally published in The Gray Sheet
Executive Summary
Firm’s therascreen KRAS test will guide Erbitux drug treatment for patients with metastatic colorectal cancer following FDA approval, announced July 6. About 110,000 U.S. patients annually could benefit from the test for the indication, representing a $20 million market opportunity.